207 related articles for article (PubMed ID: 9256160)
1. Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression.
van Triest B; Pinedo HM; Telleman F; van der Wilt CL; Jansen G; Peters GJ
Biochem Pharmacol; 1997 Jun; 53(12):1855-66. PubMed ID: 9256160
[TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the study of rTS proteins. rTS expression during growth and in response to thymidylate synthase inhibitors in human tumor cells.
Dolnick BJ; Lu K; Yin MB; Rustum YM
Adv Enzyme Regul; 1997; 37():95-109. PubMed ID: 9381988
[TBL] [Abstract][Full Text] [Related]
5. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.
Bergman AM; Pinedo HM; Talianidis I; Veerman G; Loves WJ; van der Wilt CL; Peters GJ
Br J Cancer; 2003 Jun; 88(12):1963-70. PubMed ID: 12799644
[TBL] [Abstract][Full Text] [Related]
6. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line.
Lu K; Yin MB; McGuire JJ; Bonmassar E; Rustum YM
Biochem Pharmacol; 1995 Jul; 50(3):391-8. PubMed ID: 7646540
[TBL] [Abstract][Full Text] [Related]
8. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
[TBL] [Abstract][Full Text] [Related]
9. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.
Temmink OH; Hoogeland MF; Fukushima M; Peters GJ
Cancer Chemother Pharmacol; 2006 Jan; 57(2):171-9. PubMed ID: 16010590
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability.
Kitchens ME; Forsthoefel AM; Barbour KW; Spencer HT; Berger FG
Mol Pharmacol; 1999 Nov; 56(5):1063-70. PubMed ID: 10531414
[TBL] [Abstract][Full Text] [Related]
11. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
12. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
Backus HH; Pinedo HM; Wouters D; Padrón JM; Molders N; van Der Wilt CL; van Groeningen CJ; Jansen G; Peters GJ
Int J Cancer; 2000 Sep; 87(6):771-8. PubMed ID: 10956384
[TBL] [Abstract][Full Text] [Related]
13. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.
Peters GJ; Backus HH; Freemantle S; van Triest B; Codacci-Pisanelli G; van der Wilt CL; Smid K; Lunec J; Calvert AH; Marsh S; McLeod HL; Bloemena E; Meijer S; Jansen G; van Groeningen CJ; Pinedo HM
Biochim Biophys Acta; 2002 Jul; 1587(2-3):194-205. PubMed ID: 12084461
[TBL] [Abstract][Full Text] [Related]
14. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
[TBL] [Abstract][Full Text] [Related]
15. Chemical synthesis and biological properties of novel fluorescent antifolates in Pgp- and MRP-overexpressing tumour cell lines.
Robson C; Wright KA; Twentyman PR; Lambert PA; Griffin RJ
Biochem Pharmacol; 1998 Oct; 56(7):807-16. PubMed ID: 9774142
[TBL] [Abstract][Full Text] [Related]
16. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
McGuire JJ; Magee KJ; Russell CA; Canestrari JM
Oncol Res; 1997; 9(3):139-47. PubMed ID: 9220499
[TBL] [Abstract][Full Text] [Related]
17. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression.
Versantvoort CH; Broxterman HJ; Pinedo HM; de Vries EG; Feller N; Kuiper CM; Lankelma J
Cancer Res; 1992 Jan; 52(1):17-23. PubMed ID: 1309222
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
[TBL] [Abstract][Full Text] [Related]
19. Drug-resistant variants of Escherichia coli thymidylate synthase: effects of substitutions at Pro-254.
Fantz C; Shaw D; Jennings W; Forsthoefel A; Kitchens M; Phan J; Minor W; Lebioda L; Berger FG; Spencer HT
Mol Pharmacol; 2000 Feb; 57(2):359-66. PubMed ID: 10648646
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition.
Bijnsdorp IV; Comijn EM; Padron JM; Gmeiner WH; Peters GJ
Oncol Rep; 2007 Jul; 18(1):287-91. PubMed ID: 17549381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
